All In Biotech

Drug Trial Radar · NCT02967692

A Study of the Anti-PD1 Antibody PDR001, in Combination With Dabrafenib and Trametinib in Advanced Melanoma

A Randomized, Double-blind, Placebo-controlled, Phase III Study Comparing the Combination of PDR001, Dabrafenib and Trametinib Versus Placebo, Dabrafenib and Trametinib in Previously Untreated Patients With Unresectable or Metastatic BRAF V600 Mutant Melanoma

Last checked: Nov 20, 2026Latest source record: Sep 18, 2025 (this record)Source: ClinicalTrials.govMethods & limitations

TerminatedResults posted on the registryPivotal-lookingPhase 3. Randomized with 568 participants. This is a heuristic, not a regulatory label.

Status

Terminated

Enrollment

568

Actual

Start

Feb 17, 2017

Primary completion

Aug 11, 2020

Study completion Aug 21, 2024

Sponsor

Lead sponsor
Novartis PharmaceuticalsNovartis (NVS)
Sponsor type
Industry
First posted
Nov 18, 2016

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Randomized
Model
Parallel
Masking
Quadruple (participant, care provider, investigator, outcomes assessor)
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years, up to 100 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The purpose of this study was to evaluate safety and efficacy of the combination of an anti-PD-1 antibody (PDR001), a BRAF inhibitor (dabrafenib) and a MEK inhibitor (trametinib) in patients with BRAF V600 mutant, unresectable and metastatic melanoma.

Conditions

  • Melanoma

Interventions

  • SpartalizumabBiological

    Spartalizumab powder for solution is used in Part 1 and Part 2, and as concentrate for solution for infusion for Part 3. Spartalizumab is administered via intravenous infusion over 30 minutes once every 4 weeks

  • PlaceboOther

    Placebo is administered via intravenous infusion over 30 minutes once every 4 weeks

  • DabrafenibDrug

    Dabrafenib 150 mg capsules BID is administered orally for Days 1-28 of a 28-day cycle, in fasting conditions.

  • TrametinibDrug

    Trametinib 2 mg tablets QD is administered orally for Days 1-28 of a 28-day cycle, in fasting conditions

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Safety Run-In (Part 1): Number of Participants With Dose Limiting Toxicities (DLTs)Time frame: Up to 8 weeks (Part 1)
  2. Biomarker Cohort (Part 2): Change From Baseline in Programmed Cell Death-ligand 1 (PD-L1) Expression Upon Treatment With Spartalizumab in Combination With Dabrafenib and TrametinibTime frame: Baseline, Cycle 1 Day 15 and Cycle 3 Day 1 (Part 2). Each cycle is 28 days
  3. Biomarker Cohort (Part 2): Change From Baseline in CD8+ Cells Upon Treatment With Spartalizumab in Combination With Dabrafenib and TrametinibTime frame: Baseline, Cycle 1 Day 15 and Cycle 3 Day 1 (Part 2). Each cycle is 28 days
  4. Randomized (Part 3): Progression-Free Survival (PFS) as Per Investigator's Assessment by RECIST 1.1Time frame: Up to disease progression or death due to any cause, whichever occurs first, assessed up to 2.8 years (Part 3)

Locations

179 sites in 29 countries. Site status is shown where the registry gives one.

  • California Cancer Associates for Research and Excellence

    Encinitas, California

  • UC Irvine Medical Center

    Orange, California

  • California Pacific Medical Center

    San Francisco, California

  • Stanford Cancer Center

    Stanford, California

  • University of Kansas Cancer Center

    Westwood, Kansas

  • Johns Hopkins U

    Lutherville, Maryland

  • Nebraska Cancer Specialists

    Omaha, Nebraska

  • NYU Laura and Isaac Perlmutter Cancer Center

    New York, New York

  • University of Pittsburgh Med Center

    Pittsburgh, Pennsylvania

  • University of Tennessee Medical Ctr

    Knoxville, Tennessee

  • Univ of TX MD Anderson Cancer Cntr

    Houston, Texas

  • Utah Cancer Specialists

    Salt Lake City, Utah

  • Novartis Investigative Site

    Caba, Argentina

  • Novartis Investigative Site

    CABA, Buenos Aires, Argentina

  • Novartis Investigative Site

    CABA, Buenos Aires, Argentina

  • Novartis Investigative Site

    Rosario, Santa Fe Province, Argentina

  • Novartis Investigative Site

    Gateshead, New South Wales, Australia

  • Novartis Investigative Site

    North Sydney, New South Wales, Australia

  • Novartis Investigative Site

    Greenslopes, Queensland, Australia

  • Novartis Investigative Site

    Melbourne, Victoria, Australia

  • Novartis Investigative Site

    Nedlands, Western Australia, Australia

  • Novartis Investigative Site

    Graz, Austria

  • Novartis Investigative Site

    Linz, Austria

  • Novartis Investigative Site

    Salzburg, Austria

  • Novartis Investigative Site

    Sankt Pölten, Austria

  • Novartis Investigative Site

    Innsbruck, Tyrol, Austria

  • Novartis Investigative Site

    Brussels, Belgium

  • Novartis Investigative Site

    Brussels, Belgium

  • Novartis Investigative Site

    Rio de Janeiro, Brazil

  • Novartis Investigative Site

    Curitiba, Paraná, Brazil

  • Novartis Investigative Site

    Porto Alegre, Rio Grande do Sul, Brazil

  • Novartis Investigative Site

    São Paulo, São Paulo, Brazil

  • Novartis Investigative Site

    Plovdiv, Bulgaria

  • Novartis Investigative Site

    Sofia, Bulgaria

  • Novartis Investigative Site

    Vancouver, British Columbia, Canada

  • Novartis Investigative Site

    Toronto, Ontario, Canada

  • Novartis Investigative Site

    Montreal, Quebec, Canada

  • Novartis Investigative Site

    Montreal, Quebec, Canada

  • Novartis Investigative Site

    Sherbrooke, Quebec, Canada

  • Novartis Investigative Site

    Santiago, Chile

Showing 40 of 179 sites, US sites first. The full list is on the registry record.

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.